About Us
Elan is a neuroscience-based biotechnology company headquartered in Dublin, Ireland. It was incorporated as a private limited company in December 1969 and became a public limited company in January 1984. Elan’s principal research and development, manufacturing and marketing facilities are located in Ireland and the United States.
Elan is organized into two business units: Biopharmaceuticals and Elan Drug Technologies.
Biopharmaceuticals
Biopharmaceuticals includes research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease; autoimmune diseases, including multiple sclerosis and Crohn’s disease; and severe chronic pain.
Elan Drug Technologies
Elan Drug Technologies (EDT) the world’s leading drug delivery business, develops and manufactures innovative pharmaceuticals using its extensive experience and proprietary drug technologies in partnership with pharmaceutical companies. For 40 years, EDT has enhanced the performance of dozens of drugs that are marketed and used by millions of patients.
JANSSEN Alzheimer Immunotherapy
Elan and Johnson & Johnson announced on September 17, 2009, that JANSSEN Alzheimer Immunotherapy, a Johnson & Johnson affiliate, had acquired substantially all of Elan’s assets related to the Alzheimer’s Immunotherapy Program (AIP) that Elan shared with Wyeth. Elan holds a 49.9% equity interest in JANSSEN Alzheimer Immunotherapy, and will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of AIP products.
JANSSEN Alzheimer Immunotherapy is continuing the AIP activities with Pfizer, which acquired Wyeth in 2009, to research, develop and commercialize selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease. The program includes multiple compounds being evaluated for slowing the progression of Alzheimer's disease.
The lead compound (bapineuzumab), a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, is administered intravenously once every three months and is in Phase 3 clinical trials. A subcutaneous formulation, administered once a week, is in Phase 2 trials. In addition, a vaccine for Alzheimer's disease (ACC-001) is also under development. (Learn more about AIP clinical trials).
Marketed Products
TYSABRI®
TYSABRI (natalizumab) is an approved therapy for relapsing forms of multiple sclerosis in the United States and relapsing-remitting multiple sclerosis in the European Union. TYSABRI is approved in the U.S. for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease (CD) with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-alpha.
Important Product Safety Information TYSABRI MS
Important Product Safety Information TYSABRI Crohn's
PRIALT®
PRIALT (ziconotide) is indicated in the U.S. for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or IT morphine.
Important Product Safety Information
Maxipime® and Azactam®
Elan distributes Maxipime and Azactam, which are injectable antibiotics licensed from Bristol-Myers Squibb Company to treat severe bacterial infections in a hospital environment. Maxipime is a cephalosporin antibiotic to fight serious or life-threatening infections, and Azactam is a monobactam antibiotic that is principally used to treat pneumonia, post-surgical infections and septicemia. While Maxipime and Azactam are available through distributors, we no longer promote these products.
Please see the Products section for prescribing information and Important Safety Information.
Key Facts
Locations
Athlone, Ireland
Bermuda
Dublin, Ireland (Headquarters)
Gainesville, Georgia
King of Prussia, Pennsylvania
South San Francisco, California
Employees: Approximately 1,500 worldwide
Company Registration
Elan Corporation, plc
Registered Office: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland
Registered in Ireland
Registration Number 30356
Stock Exchange Listings
New York Stock Exchange (ELN)
Irish Stock Exchange (ELN.I)
Investor Contacts
Chris Burns SVP, Global Investor Relations
Tel: 800-252-3526
Email: InvestorUS@elan.com
David Marshall PhD, VP, Global Investor Relations
Tel: 353-1-709-4444
Email: InvestorEurope@elan.com
Global Media Contact
Mary Stutts, SVP, Corporate Relations: 866-964-8256
AZACTAM is a registered trademark of Elan Pharmaceuticals, Inc.
MAXIPIME is a registered trademark of Bristol-Myers Squibb Company and licensed exclusively in the U.S.to Elan Pharmaceuticals, Inc.
